DNAP
SARASOTA, Fla.--(BUSINESS WIRE)--Aug. 8, 2000--DNAPrint genomics,
Inc., (Pink Sheets:DNAP), a Sarasota, Florida based genomics
company, announced today that it has engaged the Sarasota, Florida CPA
firm of Howard Wolmerdorph, C.P.A., P.A., to complete its audits
through December 31, 1999.
Wolmerdorph has served as auditor for the Company's genomics
operations and replaces the previous auditor, HJ & Associates, of Salt
Lake City, Utah. There were no disagreements or outstanding issues
with the prior auditor.
Chief Scientific Officer, Dr. Tony Frudakis stated, "We are
pleased to add the Howard Wolmerdorph, C.P.A., P.A., firm to our
growing team of support professionals. The Wolmerdorph firm is
familiar with the genomics research industry and is committed to a
rapid completion of the Company's reporting requirements. The
Wolmerdorph firm anticipates completing the audit process within 45
days and having the necessary documents completed in order for the
Company to become a reporting company with the Securities and Exchange
Commission prior to the end of the year."
The Company also thanked HJ & Associates for their many years of
service to the Company.
About DNAPrint genomics
DNAPrint genomics, Inc. will provide practitioners of genomics
research and personalized medicine with a comprehensive system for
disease dissection and patient classification. Health care
professionals and biopharmaceutical scientists will be able to use the
company's system, through a combination of on-site hardware/software
placement and ASP (application-service provider) resources, to draw
highly sophisticated conclusions and associations between genotype
(SNP an haplotype) data and phenotypic traits (such as drug response
or disease). The analytical heart of the system is a collection of
sophisticated algorithms that enable a quantitative and multivariate
dissection of high-density genotype matrices in complex genetic terms
for various human diseases and drug-interaction traits. The system
uses a variety of novel mathematical modeling and programming
techniques. The company is applying its informatics platform to
real-world pharmacogenomic study in order to build a portfolio of
clinical "solutions" that mathematically express the nature of the
genotype-phenotype relationship for a given drug. Each "solution" will
be used by DNAPrint genomics customers as a template against which
they can screen clinical unknowns. The Company has already filed
patent applications for a genetic analysis reagent that confers
considerable advantages for high-throughput DNA sequencing and
genotyping. The company intends to patent the application of its
informatics platform to the field of genomic research and for
personalized medical applications, as well as each pharmacogenomic and
disease "solution" that it generates as a unique, predictive and
preventative diagnostic or "diagnomic" product. DNAPrint genomics Inc.
was founded by a group of scientists with research and commercial
experience in high-level mathematical modeling, programming and
molecular genetics. For more information about the company, please
visit www.dnaprint.com.
Except for factual statements made herein, the information
contained in this press release consists of forward-looking statements
that involve risks and uncertainties. The Company's actual results
could differ materially from those contained in such statements.
Factors that could cause or contribute to such differences include
unexpected shortages of critical components, rescheduling or
cancellation of customer orders, the timing and market acceptance of
new product introductions by the Company and its competitors, and
general competition and price pressures in the marketplace.
--30--pp/mi*
CONTACT: For scientific inquiries:
DNAPrint genomics, Inc., Sarasota
Dr. Tony Frudakis, 941/351-4543
or
All other inquiries:
Richard Craig Hall, 941/341-0136
KEYWORD: FLORIDA
INDUSTRY KEYWORD: BANKING MEDICAL BIOTECHNOLOGY HARDWARE SOFTWARE
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com |
